GeneCentric Therapeutics Acquires Select ImmunoGenomics

▤ Summary

GeneCentric Therapeutics acquired Select ImmunoGenomics to expand its RNA-based precision oncology capabilities. The combined company now offers integrated immunogenomic, data analysis, and biomarker development services for drug development. GeneCentric says the deal strengthens its ability to identify patient responder populations and support pharmaceutical, biotechnology, and diagnostics partners. The acquisition did not disclose financial terms, and the two founders of Select ImmunoGenomics will remain involved as advisors.

▦ Linked Companies